For instance, in the realm of signaling pathway activation, resistance to EGFR mAb like cetuximab and panitumumab in metastatic CRC can manifest via mutations in KRAS, BRAF, PIK3CA, or PTEN. 364 Osimertinib, a third-generation EGFR-TKI, demonstrates notable efficacy against EGFR-mutated NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.